MGTA Magenta Therapeutics Inc.

13.47
+0.42  (+3%)
Previous Close 13.05
Open 12.92
Price To Book 3.95
Market Cap 529,299,946
Shares 39,294,725
Volume 39,986
Short Ratio
Av. Daily Volume 160,413

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Will evaluate development as less toxic conditioning becomes available.
MGTA-456
Sickle cell disease
Phase 2 data noted all patients met primary endpoint.
MGTA-456
Inherited Metabolic Disorders (IMD)
Phase 2 data due at ASH 2019.
MGTA-456
Acute Lymphoblastic Leukemia
Phase 1 initiation of dosing announced April 24, 2019. Initial data due at ASH 2019.
MGTA-145
Healthy volunteers

Latest News

  1. CORRECTING and REPLACING Magenta Therapeutics Appoints Anne McGeorge to Board of Directors
  2. Magenta Therapeutics Appoints Anne McGeorge to Board of Directors
  3. Can You Imagine How Magenta Therapeutics's (NASDAQ:MGTA) Shareholders Feel About The 12% Share Price Increase?
  4. Magenta Therapeutics to Present at the 40th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11th
  5. Magenta Therapeutics Reports First Quarter 2019 Financial Results and Recent Business Highlights
  6. Magenta Therapeutics Presents Updated Phase 2 Clinical Data on MGTA-456 Cell Therapy at American Academy of Neurology Annual Meeting
  7. Magenta Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
  8. Magenta Therapeutics Announces Pricing of Public Offering
  9. Magenta Therapeutics Launches Proposed Public Offering
  10. Magenta Therapeutics to Present Preclinical Data on E478 Stem Cell Gene Therapy Expansion Program at the 2019 Annual Meeting of the American Society of Gene and Cell Therapy
  11. Magenta Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of MGTA-145, a First-Line Stem Cell Mobilization Product Candidate
  12. 3 Stocks That Have More Than Tripled So Far in 2019
  13. Raymond James Thinks Magenta Still Has Upside
  14. Magenta Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights
  15. How Many Insiders Bought Magenta Therapeutics, Inc. (NASDAQ:MGTA) Shares?
  16. Magenta Therapeutics to Present at Investor Conferences in March
  17. Magenta Therapeutics Presents Preclinical Data on Targeted Non-Genotoxic Conditioning Programs, Including First Conditioning Development Candidate
  18. Magenta Therapeutics Presents Clinical and Preclinical Data on MGTA-456 Cell Therapy in Best Abstracts Sessions at Transplant and Cellular Therapy (TCT) Annual Meeting
  19. Magenta Therapeutics Presents Preclinical Data on MGTA-145, First-Line Stem Cell Mobilization Product Candidate for Autologous and Allogeneic Bone Marrow Transplant